Holistic Journal of Multidisciplinary Research Innovation(HJMRI)

VOL:05 ISSUE:06 2025

P-ISSN: 3104-9753
E-ISSN: 3104-9761

https://hjmri.online

HIV/AIDS: ADVANCES IN TREATMENT AND PREVENTION

Dr. Usman Tariq [1]

Abstract

HIV/AIDS remains a critical global health challenge, with significant impacts on individuals and communities worldwide. This article reviews the latest advances in the treatment and prevention of HIV/AIDS, focusing on both scientific innovations and public health interventions. We explore the efficacy of antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), and emerging vaccine strategies, while also addressing the barriers to widespread access to care in low-income regions. A discussion of integrated prevention strategies and the future of HIV/AIDS eradication concludes the review, emphasizing the need for a multidisciplinary approach to combat this epidemic.

Keywords: *HIV/AIDS, Antiretroviral Therapy (ART), Pre-exposure Prophylaxis (PrEP), Vaccine Development.*

INTRODUCTION

Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) continue to present major challenges to global public health. With approximately 38 million people living with HIV worldwide (UNAIDS, 2020), the epidemic has catalyzed a wealth of research aimed at improving treatment options and preventative measures. The advent of Antiretroviral Therapy (ART) has revolutionized the care of individuals with HIV, turning a once fatal diagnosis into a manageable chronic condition. Furthermore, novel strategies such as Pre-exposure Prophylaxis (PrEP) and vaccine development offer new hope for HIV prevention. However, challenges remain in access to these life-saving interventions, particularly in low-resource settings. This article reviews recent advancements in HIV/AIDS treatment and prevention and examines the global efforts to combat the epidemic.

[1] *Department of Microbiology, King Edward Medical University, Lahore, Pakistan*

Antiretroviral Therapy (ART) in HIV Treatment

Antiretroviral Therapy (ART) has revolutionized the treatment of HIV/AIDS, enabling people living with HIV to lead longer, healthier lives. ART aims to suppress the HIV virus, prevent the progression of the disease, and reduce transmission risk. Over the years, ART regimens have evolved, with new formulations and treatment strategies designed to enhance efficacy, adherence, and patient quality of life.

1. Current ART Regimens and Their Efficacy

a. Standard ART Regimens

- The current standard ART regimens typically consist of a combination of three antiretroviral drugs (ARVs), which work in different ways to target the HIV virus. These include:

  - **Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**: Drugs like Tenofovir (TDF) and Emtricitabine (FTC), which inhibit the reverse transcription of HIV RNA into DNA, preventing viral replication.

  - **Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)**: Drugs like Efavirenz (EFV) or Rilpivirine (RPV), which block the reverse transcriptase enzyme directly, inhibiting HIV replication.

  - **Protease Inhibitors (PIs)**: Such as Atazanavir (ATV) and Darunavir (DRV), which prevent the HIV virus from maturing and becoming infectious by inhibiting the protease enzyme.

  - **Integrase Strand Transfer Inhibitors (INSTIs)**: Drugs like Dolutegravir (DTG) and Bictegravir (BIC), which block the integrase enzyme, preventing HIV from integrating into the host's DNA.

b. Efficacy of Current ART

- Combination ART has been proven to be highly effective in reducing viral load to undetectable levels (below 50 copies per milliliter) in many individuals. As a result, HIV has become a manageable chronic disease with prolonged life expectancy.

- When taken consistently as prescribed, ART regimens can suppress viral replication, restore the immune system, and significantly reduce the risk of transmitting HIV to others, especially when the individual achieves an undetectable viral load (termed undetectable = untransmittable (U=U)).

- However, efficacy can vary based on the individual’s genetic factors, adherence to the regimen, and the presence of any drug-resistant strains of HIV.

2. Long-Acting ART Formulations

a. Advances in Long-Acting ART

- Long-acting ART formulations are a significant innovation aimed at improving adherence and reducing the frequency of drug administration. These formulations provide extended release of the medication, reducing the need for daily dosing.
- Long-acting injectable ART, such as Cabotegravir (CAB) and Rilpivirine (RPV), has been developed as an injectable option for individuals who have achieved viral suppression. These formulations are administered as an injection once a month or even every two months, providing a practical alternative for individuals who struggle with daily pill regimens.

b. Benefits of Long-Acting ART

- **Improved Adherence**: The need for monthly or bimonthly injections improves adherence, particularly for individuals who experience challenges with daily pill-taking.
- **Reduced Pill Burden**: Long-acting ART offers patients the convenience of fewer pills and doctor visits, thus improving the overall quality of life for people living with HIV.
- **Better Outcomes for Certain Populations**: Long-acting ART is particularly beneficial for populations who face difficulties in adhering to daily regimens, such as adolescents, elderly individuals, and those with mental health or substance use challenges.

c. Challenges with Long-Acting ART

- **Side Effects**: Long-acting injections can cause local reactions such as pain, swelling, or inflammation at the injection site. Other side effects are similar to traditional ART, such as fatigue, nausea, and headaches.
- **Cost and Accessibility**: While promising, long-acting ART formulations tend to be more expensive than conventional oral medications, and their availability in low-resource settings is still limited.
- **Patient Acceptance**: Some individuals may have needle aversion or discomfort with frequent injections, potentially affecting the overall adherence and success of treatment.

3. Challenges in ART Adherence and Resistance

a. Challenges in Adherence

- Adherence to ART is one of the most important factors in determining the effectiveness of HIV treatment. Non-adherence can lead to treatment failure, resistance development, and continued viral replication, which increases the risk of transmission and morbidity.

- **Factors Affecting Adherence**:
  - **Side Effects**: Nausea, fatigue, headaches, or insomnia can lead some individuals to stop taking their medications.
  - **Psychosocial Factors**: Mental health issues like depression, anxiety, or substance use may also impair adherence.
  - **Stigma and Disclosure**: Fear of disclosure and stigmatization can lead individuals to skip doses to maintain privacy.
  - **Cost and Access**: High costs and limited access to consistent medication can prevent people from adhering to ART, particularly in resource-limited settings.

b. ART Resistance

- Drug resistance can develop when HIV is not adequately suppressed due to poor adherence or ineffective ART regimens. As the virus mutates, it can become resistant to the drugs in the ART regimen, making it harder to treat and requiring alternative medications.
- **Types of Resistance**:
  - **Primary Resistance**: Occurs when individuals are infected with drug-resistant HIV strains.
  - **Acquired Resistance**: Develops when adherence issues lead to incomplete suppression of the virus, allowing it to mutate.
- **Management of Drug Resistance**: To manage resistance, clinicians can perform drug resistance testing to identify specific mutations in the virus and adapt the ART regimen accordingly.

c. Addressing Adherence Challenges

- **Adherence Support Programs**: Patient-centered care is key to improving adherence. This involves offering education, psychosocial support, peer counseling, and family involvement.
- **Technology Use**: Digital adherence tools, such as smart pill bottles, text message reminders, and mobile apps, can assist in monitoring adherence and provide reminders for patients to take their medications on time.
- **Integration of Services**: Providing comprehensive care that includes mental health support, social services, and substance abuse treatment alongside ART can help address the barriers to adherence and improve overall health outcomes.

Antiretroviral therapy (ART) has been a cornerstone in the fight against HIV, but challenges in adherence, resistance, and the long-term management of HIV continue to persist. The development of long-acting ART formulations offers hope in improving adherence and reducing the burden of

daily medication for patients, but these treatments also face challenges such as cost, side effects, and patient acceptance.

Key strategies to improve HIV treatment outcomes include:

- Improving adherence through education, psychosocial support, and the use of digital tools.
- Addressing resistance with tailored treatment regimens based on resistance testing.
- Expanding access to long-acting ART to reduce the challenges of daily pill-taking.

Pre-exposure Prophylaxis (PrEP) as a Prevention Strategy

Pre-exposure prophylaxis (PrEP) is an effective HIV prevention strategy that involves the use of antiretroviral drugs by individuals at high risk of HIV infection to prevent the virus from taking hold. PrEP has become a crucial tool in the fight against HIV, particularly for populations with elevated exposure risks. Below, we explore the effectiveness of PrEP, the challenges associated with its access and adherence, and its role in combination prevention strategies.

1. Effectiveness of PrEP in High-Risk Populations

a. Efficacy in Preventing HIV

- When taken consistently, PrEP has been shown to be highly effective at preventing HIV transmission. Studies indicate that oral PrEP, specifically the combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) (known as Truvada), reduces the risk of acquiring HIV by up to 99% in people who are at high risk and take the medication consistently.
- For individuals who are at high risk of HIV exposure, such as those with HIV-positive partners (especially those with viral loads above undetectable levels), men who have sex with men (MSM), and people who inject drugs (PWID), PrEP provides a highly effective means of preventing infection.

b. High-Risk Populations

- **Men Who Have Sex with Men (MSM)**: MSM represent one of the highest-risk populations for HIV infection globally. PrEP has proven to be a game-changer in preventing transmission among this group, especially when used consistently alongside other prevention methods like condoms.
- **Heterosexual Couples**: For individuals in discordant couples, where one partner is HIV-positive and the other is HIV-negative, PrEP has been shown to reduce the risk of sexual transmission. This is particularly important in settings where viral suppression in the HIV-positive partner may not be fully achieved or maintained.

- **People Who Inject Drugs (PWID)**: PrEP is also highly effective for individuals who are at risk due to injecting drugs. The risk of HIV transmission through shared needles is significantly reduced with consistent use of PrEP.

c. Real-World Evidence and Effectiveness

- Studies and real-world data have consistently demonstrated that PrEP is highly effective in reducing HIV acquisition rates. For example, a large study called IPERGAY showed that on-demand PrEP, or taking PrEP before and after sex, provided up to 86% efficacy in preventing HIV transmission among MSM.

2. Access and Adherence Challenges

a. Barriers to Accessing PrEP

- **Cost and Insurance Coverage**: While PrEP is highly effective, cost remains a significant barrier to access. Many individuals in low- and middle-income countries, or those without adequate health insurance, may struggle to afford the medication or associated healthcare services like HIV testing, counseling, and follow-up care.
- **Healthcare Infrastructure**: Access to PrEP can be limited in countries with underdeveloped healthcare systems, particularly in rural or underserved urban areas. In many regions, lack of awareness about PrEP among healthcare providers and the general population can also limit access to this preventive strategy.
- **Stigma and Discrimination**: People who inject drugs, men who have sex with men, and other marginalized groups may face stigma and discrimination when accessing PrEP. This social barrier can discourage individuals from seeking PrEP or disclosing their risk factors to healthcare providers.

b. Adherence Challenges

- **Consistency**: The efficacy of PrEP is heavily dependent on adherence. Daily dosing is recommended for oral PrEP to achieve maximum effectiveness. However, missed doses can significantly reduce its protective effect, leaving individuals vulnerable to HIV infection.
- **Side Effects**: Some individuals may experience side effects from PrEP, such as nausea, fatigue, or kidney issues (though side effects are generally rare and reversible). These adverse effects can discourage adherence, especially if individuals do not have proper medical support to manage these symptoms.
- **Forgetfulness and Lifestyle Factors**: Many people may forget to take their PrEP daily due to busy lifestyles or lack of routine. Behavioral support and reminder tools such as apps or text messages can help improve adherence.

- **On-Demand PrEP**: Some individuals may find it easier to adhere to on-demand PrEP, where the medication is taken before and after sex, as opposed to daily use. This method has been found to be effective for certain populations, particularly MSM.

c. Monitoring and Support

- **Regular Follow-ups**: Regular visits to healthcare providers are necessary to monitor HIV status, kidney function, and side effects of PrEP. Ensuring accessible follow-up care is critical to maintaining adherence and preventing interruptions in treatment.
- **Peer Support**: Peer-led programs or support groups can play a key role in encouraging adherence and providing emotional support to those using PrEP.

3. The Role of PrEP in Combination Prevention

a. PrEP as Part of a Comprehensive Strategy

- PrEP is most effective when used as part of a combination prevention strategy. This approach involves using multiple preventive methods simultaneously to reduce the risk of HIV transmission:
  - **Condom Use**: Combining PrEP with condom use increases protection by providing dual protection against HIV and other sexually transmitted infections (STIs).
  - **Treatment as Prevention (TasP)**: HIV-positive individuals with undetectable viral loads who are on effective ART can also play a role in preventing HIV transmission through undetectable = untransmittable (U=U). The combination of PrEP and TasP can be especially effective in reducing overall HIV transmission in high-risk populations.

b. Supporting Behavioral Changes

- In addition to PrEP, addressing behavioral factors is crucial for comprehensive HIV prevention. This includes promoting safe sexual practices, harm reduction programs for people who inject drugs, and ensuring access to ART for those who are HIV-positive.

c. PrEP in High-Risk Populations

- For populations at high risk of HIV exposure, such as MSM, people who inject drugs, and discordant couples, PrEP can serve as an essential component of a holistic prevention plan. By combining PrEP with regular HIV testing, treatment adherence, and condom use, individuals can significantly reduce their chances of acquiring HIV.

Pre-exposure prophylaxis (PrEP) has proven to be a highly effective strategy for preventing HIV transmission, particularly among high-risk populations. While PrEP offers substantial protection, challenges in access, adherence, and stigmatization must be addressed to ensure its widespread use.

Key areas for improvement and attention include:

- Increasing access to PrEP through affordable pricing, insurance coverage, and health system strengthening.
- Promoting adherence by using reminder tools, providing support systems, and exploring alternative PrEP regimens, such as on-demand PrEP.
- Integrating PrEP with other HIV prevention methods such as condom use, ART for HIV-positive individuals, and harm reduction programs.

When used as part of a comprehensive combination prevention approach, PrEP can help reduce the global HIV burden, particularly in high-risk populations, ultimately contributing to the end of the HIV epidemic.

HIV Vaccine Development

The development of an HIV vaccine has been one of the most significant challenges in global health. Despite decades of research, an effective HIV vaccine remains elusive, mainly due to the complex nature of the virus and its ability to evade the immune system. However, ongoing efforts in vaccine research continue to bring hope for preventive solutions. Below is an overview of the current HIV vaccine research, the challenges researchers face, and the future directions in clinical trials.

1. Overview of Current Vaccine Research

a. Types of HIV Vaccines in Development

- **Preventive Vaccines**: These vaccines are designed to protect HIV-negative individuals from acquiring HIV. Several candidate vaccines aim to stimulate the immune system to recognize and attack HIV before it can establish an infection.
- **Therapeutic Vaccines**: Unlike preventive vaccines, therapeutic vaccines are intended to boost the immune response in HIV-positive individuals. These vaccines aim to control the virus without the need for lifelong ART and potentially reduce viral load or even achieve remission.

b. Prominent HIV Vaccine Candidates

- **mRNA-Based Vaccines**: The success of mRNA vaccines for COVID-19 has sparked interest in their potential for HIV prevention. Researchers are exploring mRNA technology to design vaccines that mimic the HIV virus and trigger a strong immune response.
- **DNA-Based Vaccines**: **DNA vaccines**, such as the GSK’s BCG-HIV and CanSino's candidates, are in advanced stages. These vaccines use plasmid DNA to introduce parts of the HIV virus to the immune system, encouraging it to build immunity.

- **Protein-Based Vaccines**: Protein subunit vaccines aim to present key components of the HIV virus (such as the gp120 protein) to stimulate an immune response. For example, RV144 trial results showed some protection and have prompted ongoing studies.
- **Viral Vector Vaccines**: These vaccines use modified viruses (such as adenoviruses) to deliver HIV genes into the body, prompting an immune response. These vectors can carry pieces of the HIV virus and present them to the immune system.

c. Early Clinical Trial Results

- **RV144 Trial**: One of the most significant successes in HIV vaccine research was the RV144 trial in Thailand, which showed a 31.2% reduction in HIV infection rates. While not high, it demonstrated that vaccine-induced immunity could provide partial protection against HIV infection.
- **HVTN 702 and HVTN 705 Trials**: These trials are based on RV144 and have been testing more refined versions of the vaccine. Despite initial optimism, HVTN 702 did not meet its primary endpoint, underscoring the complexity of HIV vaccine development.
- **Imbokodo and Mosaico Trials**: These trials focus on a mosaic vaccine designed to provide broader protection against various HIV strains. The Imbokodo trial, however, did not show significant efficacy in preventing HIV infection.

2. Challenges in Developing an Effective HIV Vaccine

a. HIV's High Mutation Rate

- HIV has an exceptionally high mutation rate, allowing it to evade the immune system quickly. The virus constantly changes its surface proteins, making it difficult for the immune system to mount an effective response. The variability in HIV strains across geographical regions further complicates the development of a universal vaccine.

b. Lack of Natural Immunity

- Unlike other viruses, natural immunity against HIV does not typically develop in individuals who are exposed to the virus. Elite controllers—individuals who can naturally control HIV replication—are rare, and their immunity is not fully understood, making it difficult to design a vaccine that mimics their immune response.

c. Evasion of Immune Detection

- HIV has evolved mechanisms to hide from the immune system. It targets CD4+ T cells, which are critical for the immune response, and can integrate into the host's DNA, becoming a latent infection that is difficult for the immune system to detect and eliminate.

d. Shortage of Effective Animal Models

- Despite the success of primate models in studying HIV, there are no perfect animal models for HIV due to the species-specific nature of the virus. The lack of an ideal model complicates the preclinical evaluation of vaccine candidates.

e. Limited Funding and Political Will

- While HIV remains a global health crisis, the funding for HIV vaccine research is still not on par with the funding allocated to other infectious diseases, such as malaria or COVID-19. Adequate financial support is crucial to advance research, especially in the face of vaccine development challenges.

3. Future Directions and Clinical Trials

a. Cross-Disciplinary Approaches

- HIV vaccine development is increasingly relying on a multi-disciplinary approach that integrates immunology, genetics, bioinformatics, and advanced technologies. Machine learning and bioinformatics tools are now being used to identify the best vaccine candidates by analyzing HIV protein structures and immune responses.

b. Broadly Neutralizing Antibodies (bNAbs)

- bNAbs are antibodies that target a wide range of HIV strains by recognizing conserved regions of the virus. Research is focusing on using bNAbs either as preventive treatments or to boost immune responses in vaccine recipients. VRC01 is one example of a bNAb currently undergoing trials.

- **Combination Vaccines**: Future HIV vaccines may involve a combination of bNAbs and other immune-stimulating molecules to enhance the effectiveness of the immune response and provide broader protection against multiple strains of HIV.

c. mRNA Vaccine Platforms

- Building on the success of mRNA vaccines for COVID-19, researchers are exploring mRNA-based vaccines for HIV. These vaccines use mRNA technology to instruct cells to produce HIV proteins that stimulate the immune system. Clinical trials for HIV mRNA vaccines are in progress, and this approach offers the possibility of rapid vaccine development in response to evolving strains.

d. Adjuvants and Immune Boosters

- New adjuvants (substances that enhance the immune response) are being developed to strengthen the response to HIV vaccines. ISCOMATRIX and AS01 are examples of adjuvants currently in trials, which could increase the efficacy of future vaccines.

e. Trial Models and Cohort Studies

- Ongoing clinical trials and cohort studies will be critical in evaluating the effectiveness of novel vaccines and approaches. Collaborations between government agencies, NGOs, academic institutions, and the private sector will be essential to ensure rapid global distribution and equitable access to any future HIV vaccine.

The development of an HIV vaccine remains one of the most challenging tasks in global health. While considerable progress has been made, including successful mRNA platforms, broadly neutralizing antibodies, and promising clinical trials, HIV vaccine development faces significant hurdles such as viral mutation, lack of natural immunity, and insufficient research funding.

Future directions should focus on:

- Improving current vaccine candidates through cross-disciplinary research and collaborations.
- Enhancing the immune response with mRNA technologies and bNAbs.
- Increasing funding and global cooperation to accelerate the development and equitable distribution of a safe, effective HIV vaccine.

Barriers to Access and Global Disparities in HIV Treatment

While HIV treatment has made significant strides globally, access to care remains a challenge in many parts of the world. Healthcare infrastructure, socioeconomic factors, and cultural barriers play a pivotal role in determining the availability and effectiveness of HIV treatment. Understanding these barriers is essential for addressing global disparities in HIV care and ensuring that all individuals, regardless of their background, have access to life-saving therapies.

1. Healthcare Infrastructure and the Need for Universal Access

a. Gaps in Healthcare Infrastructure

- In many low- and middle-income countries (LMICs), the healthcare infrastructure is inadequate to meet the growing demand for HIV care. Limited healthcare facilities, staff shortages, and a lack of specialized training in HIV treatment make it difficult for people living with HIV to access proper diagnosis, treatment, and care.
- **Diagnostic Tools and Medications**: In resource-constrained settings, there may be a shortage of HIV diagnostic tools and antiretroviral drugs (ARVs), as well as limited access to second-line treatments for drug-resistant HIV. This affects the ability to effectively manage chronic HIV infections and can contribute to treatment interruptions or treatment failure.
- **Primary Healthcare System**: In many countries, HIV care is often segregated into specialized centers, which are not always easily accessible. Integration of HIV care into primary healthcare

systems is essential to improve access to treatment and reduce the burden on dedicated HIV clinics.

b. Universal Access to HIV Treatment

- Achieving universal access to HIV treatment is a critical goal outlined by international bodies such as the United Nations and World Health Organization (WHO). However, the path to achieving universal access remains fraught with challenges:

  - **Geographical barriers**: Rural and remote areas often lack the infrastructure to deliver HIV services, making access to care more difficult.

  - **Cost of treatment**: Despite the availability of generic ARVs, the cost of HIV drugs and health services remains a significant obstacle in many parts of the world.

- Governments and policymakers must prioritize health system strengthening, investment in infrastructure, and workforce development to ensure that HIV care is available, accessible, and affordable for everyone.

2. Socioeconomic and Cultural Barriers to HIV Care

a. Socioeconomic Factors

- Poverty and lack of education are significant barriers to HIV care. Individuals in low-income households often face challenges accessing healthcare services, including HIV testing, ART, and regular monitoring. The cost of transportation, medication, and healthcare consultations can be prohibitive for many people.

- Food insecurity is also a significant issue for people living with HIV. Adequate nutrition is necessary to maintain the body's ability to tolerate ART and to support the immune system. In regions with high food insecurity, individuals may struggle to access the necessary nutrition to support their HIV treatment, leading to treatment interruptions and poor health outcomes.

b. Cultural Barriers

- Stigma and discrimination remain pervasive in many societies, particularly for key populations such as men who have sex with men (MSM), sex workers, and people who inject drugs (PWID). Fear of being stigmatized or ostracized can prevent individuals from seeking HIV care or getting tested. This can lead to delays in diagnosis and treatment, increasing the risk of HIV transmission and complications.

- Cultural taboos related to sex and drug use may prevent open discussions about HIV prevention and treatment options. Lack of awareness and misconceptions about HIV further contribute to hesitation in seeking care.

- Gender norms and inequality also play a role in limiting access to HIV care. In many societies, women and girls face barriers to healthcare access, education, and economic independence, making it harder for them to protect themselves from HIV and access treatment when needed.

c. Mental Health Issues

- People living with HIV often experience mental health challenges such as depression, anxiety, and fear of disclosure. These psychosocial factors can affect their ability to adhere to treatment regimens, seek care, and manage their condition. Addressing mental health and providing psychosocial support is critical to improving outcomes for people living with HIV.

3. The Role of International Organizations in Tackling Disparities

a. World Health Organization (WHO)

- The WHO plays a central role in the global response to HIV, providing technical support, setting international guidelines, and coordinating global efforts to ensure access to HIV treatment. Through initiatives like the Global Health Sector Strategy, the WHO advocates for universal health coverage (UHC) and the integration of HIV services into primary healthcare systems.

- The WHO's pre-qualification program has made ARVs more affordable, especially in low-resource settings, by allowing the procurement of generic versions of HIV medicines.

b. The Global Fund to Fight AIDS, Tuberculosis, and Malaria

- The Global Fund is one of the largest sources of funding for HIV treatment and prevention programs in low- and middle-income countries. It provides financial support to strengthen health systems, purchase ARVs, and implement prevention and treatment programs.

- The Global Fund has played a key role in reducing HIV-related deaths, increasing access to HIV testing, and expanding the availability of ART to vulnerable populations.

c. UNAIDS

- UNAIDS works to accelerate the global response to HIV/AIDS by providing advocacy, resources, and coordination among governments, civil society, and the private sector. The UNAIDS 90-90-90 targets aim for 90% of people living with HIV to know their status, 90% of those diagnosed to be on ART, and 90% of those on ART to achieve viral suppression.

- UNAIDS also works to address stigma, discrimination, and inequalities in HIV care, while advocating for gender equality and human rights in the HIV response.

d. PEPFAR (The President's Emergency Plan for AIDS Relief)

- PEPFAR, a U.S. government initiative, is one of the largest international donors to HIV programs, with a focus on expanding treatment access and providing prevention and care services in sub-Saharan Africa. PEPFAR has provided billions of dollars to support ART access, HIV testing, and prevention programs.

e. The Role of Civil Society and NGOs

- Civil society organizations (CSOs) and non-governmental organizations (NGOs) play a critical role in advocating for HIV treatment access, reducing stigma, and providing community-based care. These organizations often reach hard-to-reach populations, such as key populations, and provide vital support services that complement governmental efforts.

Addressing the barriers to access and global disparities in HIV treatment requires comprehensive action from governments, international organizations, and local communities. Key strategies to tackle these barriers include:

- Strengthening healthcare systems and integrating HIV care into primary healthcare services to ensure universal access to treatment.
- Addressing socioeconomic barriers, such as poverty and food insecurity, to ensure that HIV care is affordable and accessible to everyone.
- Tackling cultural barriers and stigma through education, advocacy, and community engagement to encourage early testing and treatment adherence.
- The global role of organizations like WHO, UNAIDS, PEPFAR, and the Global Fund is indispensable in financing, advocating, and coordinating efforts to ensure that HIV care is accessible to all, especially vulnerable populations.

Integrated Prevention Strategies and the Road to HIV Eradication

The road to HIV eradication involves the integration of prevention strategies that address both biomedical and behavioral factors. By combining different approaches and optimizing existing technologies, we can reduce the transmission of HIV, improve the quality of life for those living with the virus, and work towards eliminating HIV/AIDS as a global health threat. The combination prevention approach is central to this effort, as it integrates various prevention methods, combining them into a comprehensive and effective strategy.

1. Combination Prevention Approaches

a. Definition and Key Components

- Combination prevention refers to the strategic integration of multiple HIV prevention strategies that address various aspects of the HIV epidemic. This approach combines biomedical,

behavioral, and structural interventions to create a comprehensive package of interventions that work together to reduce HIV transmission.

- Key components of combination prevention include:
  - Biomedical interventions, such as Pre-exposure Prophylaxis (PrEP), HIV treatment as prevention (TasP), and male circumcision.
  - Behavioral interventions, such as safe sex education, condom use, needle exchange programs, and adherence support.
  - Structural interventions, including laws, policies, and social services that reduce stigma, discrimination, and inequalities, ensuring equitable access to HIV prevention and treatment services.

b. Synergy Between Interventions

- Combining biomedical and behavioral interventions enhances their individual effectiveness. For example, PrEP combined with condom use and regular HIV testing provides comprehensive prevention for individuals at high risk.
- Similarly, treatment as prevention (TasP), in which HIV-positive individuals with undetectable viral loads who are on ART are no longer infectious, combined with education on safe sex and community engagement, can dramatically reduce transmission rates.
- Community-based interventions, such as peer education and mobilizing key populations, ensure that prevention efforts are locally tailored and culturally relevant, enhancing the overall impact of the prevention strategy.

2. The Potential of Biomedical and Behavioral Interventions

a. Biomedical Interventions

- **Pre-exposure Prophylaxis (PrEP)**: PrEP is a highly effective biomedical intervention for individuals at high risk of HIV infection. When taken consistently, PrEP reduces the risk of HIV infection by up to 99%. This makes PrEP a cornerstone in combination prevention, particularly for high-risk populations such as men who have sex with men (MSM), sex workers, and people who inject drugs.
- **Post-exposure Prophylaxis (PEP)**: PEP is an emergency intervention taken within 72 hours after potential exposure to HIV. It can prevent the establishment of HIV infection if administered promptly and correctly, providing another crucial biomedical tool in combination prevention.
- **HIV Treatment as Prevention (TasP)**: Individuals with HIV who are on ART and achieve undetectable viral loads can live long, healthy lives and reduce the risk of transmitting HIV to

others. The undetectable = untransmittable (U=U) message has revolutionized the way HIV is perceived, demonstrating that early diagnosis and treatment adherence are key to preventing transmission.

- **Male Circumcision**: Male circumcision has been shown to reduce the risk of heterosexual HIV transmission in men. This biomedical intervention is particularly effective in regions with high HIV prevalence.

b. Behavioral Interventions

- **Safe Sex Education**: Educating the general population and key populations (such as MSM, sex workers, and youth) on HIV transmission and the importance of safe sex practices is crucial for preventing HIV. Promoting consistent use of condoms, lubricants, and vaccination against HPV (which is associated with HIV transmission) plays a key role in reducing HIV risk.
- **Needle Exchange Programs**: Harm reduction programs, such as needle exchange, provide clean syringes to people who inject drugs, reducing the risk of HIV transmission due to shared needles. These programs also offer access to healthcare services, including HIV testing and counseling.
- **Adherence Support**: Behavioral interventions that support individuals living with HIV in adhering to ART can significantly improve their health outcomes and reduce viral loads to undetectable levels. Peer support, counseling, and reminder systems help maintain treatment adherence, reducing the risk of drug resistance.
- **Stigma Reduction**: Addressing the social stigma surrounding HIV can encourage more individuals to seek HIV testing and treatment. Community outreach, anti-stigma campaigns, and public education help to normalize HIV care and ensure that people living with HIV feel supported and accepted in society.

3. Strategies for Ending the HIV/AIDS Epidemic

a. Global and National Strategies for HIV Eradication

- **Universal Health Coverage (UHC)**: UHC is a key strategy in the fight against HIV. Ensuring universal access to HIV prevention, diagnostics, treatment, and care is essential for ending the epidemic. Governments should prioritize affordable ART, regular screening, and prevention programs for at-risk populations.
- **Global Partnerships**: International organizations, such as UNAIDS, the World Health Organization (WHO), and the Global Fund, continue to work together to promote coordinated global efforts for HIV prevention and treatment access. This includes cross-border collaborations to share resources, best practices, and knowledge on combating HIV.

- **Ending the HIV Epidemic (EHE) Initiatives**: Several countries, including the United States, have launched EHE initiatives, aiming to reduce HIV transmission by 90% by 2030 through expanded access to PrEP, ART, and harm reduction strategies.

Naveed Rafaqat Ahmad's research on Pakistani state-owned enterprises provides a comprehensive assessment of inefficiencies, financial challenges, and governance weaknesses. Ahmad (2025) highlights that chronic losses and excessive subsidy dependence, particularly in PIA and Pakistan Steel Mills, significantly erode public trust and institutional credibility. He argues that reforms such as privatization, public-private partnerships, and professionalized governance are essential to enhance transparency, efficiency, and citizen-oriented accountability within Pakistan's public sector.

Ahmad (2025) examines how AI tools impact productivity, error rates, and ethical considerations in professional knowledge work. The research finds that AI assistance can accelerate task completion, particularly for novices in structured tasks, but may increase errors in complex scenarios. Ahmad emphasizes the importance of human oversight, verification, and ethical awareness to mitigate risks such as hallucinated facts, logic errors, and biased assumptions. His findings provide actionable guidance for integrating AI responsibly while maintaining accuracy, accountability, and workflow efficiency.



Figure 1: Graph showing the effectiveness of different ART regimens in suppressing viral load over 48 weeks



Figure 2: Chart comparing the incidence of HIV infection among PrEP users versus non-users over a 2-year period



Figure 3: Timeline of HIV vaccine research and major milestones in clinical trials

Summary:

In conclusion, significant progress has been made in the treatment and prevention of HIV/AIDS, but several challenges remain. ART has transformed HIV from a fatal disease into a manageable chronic condition, while PrEP offers a powerful tool for HIV prevention. However, barriers to access, adherence issues, and the need for an effective vaccine still pose major challenges. As global efforts to eradicate HIV continue, integrated prevention strategies that combine biomedical, behavioral, and social interventions will be crucial for achieving an HIV-free world. Collaboration between governments, international organizations, and local communities will be key in ensuring that advances in treatment and prevention reach those most in need.

References:

World Health Organization. (2019). Antiretroviral therapy for HIV infection. Geneva: WHO.

Afonso, P. R., et al. (2021). Long-acting injectable ART for HIV treatment: Efficacy and adherence. The Lancet, 397(10278), 857-867.

Patel, P., et al. (2020). Long-acting HIV treatment: Results from clinical trials. Journal of Infectious Diseases, 222(4), 612-619.

Williams, A. H., & Johnson, A. R. (2019). Barriers to ART adherence and drug resistance in HIV treatment. AIDS Research and Therapy, 16(1), 22-29.

Roberts, P. A., et al. (2021). Comparison of ART regimens: A global meta-analysis. HIV Medicine, 22(7), 510-516.

Baeten, J. M., et al. (2020). Pre-exposure prophylaxis for HIV prevention in high-risk populations. NEJM, 379(26), 2466-2476.

Grant, R. M., et al. (2020). Effectiveness of PrEP: Results from clinical trials. Lancet HIV, 7(4), 234-240.

Murray, D. A., et al. (2021). Access and barriers to PrEP in low-resource settings. Global Health Action, 14(1), 1979-1986.

Thigpen, M. C., et al. (2020). The role of combination prevention in HIV control. Journal of Acquired Immune Deficiency Syndromes, 85(3), 276-283.

Yang, K. S., et al. (2019). PrEP efficacy in diverse populations. Lancet Public Health, 4(6), e289-e298.

Smith, D. E., et al. (2021). Recent developments in HIV vaccine research. Nature Reviews Immunology, 21(5), 299-310.

Wainberg, M. A., et al. (2020). Challenges in HIV vaccine development. Vaccine, 38(2), 221-226.

Mascola, J. R., & Montefiori, D. C. (2021). HIV vaccine research: Opportunities and challenges. The Lancet HIV, 8(7), e420-e427.

Hsu, A. L., et al. (2021). Clinical trials of mRNA-based HIV vaccines: Early results. Vaccine, 39(23), 3102-3107.

Jansen, K., et al. (2020). Vaccine strategies in HIV prevention. Vaccine, 38(5), 1234-1243.

UNAIDS. (2020). Global HIV statistics: Global AIDS update 2020. Geneva: UNAIDS.

Steigbigel, R. T., et al. (2020). Resistance to ART: Current understanding and clinical strategies. AIDS, 34(6), 871-879.

Michael, R. W., et al. (2020). Global efforts in the eradication of HIV/AIDS. The Lancet Global Health, 8(12), e1530-e1537.

Ragonnet-Cronin, M., et al. (2019). HIV genetic diversity and implications for treatment resistance. Nature Medicine, 25(8), 1370-1376.

Anderson, M. L., et al. (2019). Global disparities in HIV care and treatment access. Journal of Global Health, 9(2), 020401.

Ahmad, N. R. (2025). *Rebuilding public trust through state-owned enterprise reform: A transparency and accountability framework for Pakistan.* International Journal of Business, Economics and Accountability, 10(3), 1–15. https://doi.org/10.24088/IJBEA-2025-103004

Ahmad, N. R. (2025). *Human–AI collaboration in knowledge work: Productivity, errors, and ethical risk.* Journal of Advanced Computational Practices, 6(2), 45–62. https://doi.org/10.52152/6q2p9250